Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

BACKGROUND: To compare the cardiovascular event risk in type 2 diabetes patients newly receiving dapagliflozin vs. empagliflozin. METHODS: We conducted a retrospective cohort study by analyzing a multi-institutional electronic medical records database (Chang Gung Research Database) in Taiwan and inc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Shao, Shih-Chieh, Chang, Kai-Cheng, Hung, Ming-Jui, Yang, Ning-I, Chan, Yuk-Ying, Chen, Hui-Yu, Kao Yang, Yea-Huei, Lai, Edward Chia-Cheng
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6760106/
https://ncbi.nlm.nih.gov/pubmed/31551068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0919-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados